A Belgium real-world cohort study analyzed 185 melanoma patients who chose to discontinue anti-PD-1 therapy in the absence of disease progression or toxicity, with a median treatment duration of 12 months and 1- and 2-year PFS after discontinuation of 90% and 71% (114). This evidence concerns the gene PDCD1 and melanoma.